Corinna, K., Astrid, H., Leonie, S., Valeria, M.P., Andreas, S., Udo, S., Raffi, B., & Peter, O. (2026). (Long-term) efficacy of endotype-based drug therapy on quality of life and symptom management in coronary vasomotion disorders.. International journal of cardiology.
Corinna K, Astrid H, Leonie S, Valeria MP, Andreas S, Udo S, et al. (Long-term) efficacy of endotype-based drug therapy on quality of life and symptom management in coronary vasomotion disorders.. International journal of cardiology. 2026; PMID: 42049126
Corinna K, Astrid H, Leonie S, et al. (Long-term) efficacy of endotype-based drug therapy on quality of life and symptom management in coronary vasomotion disorders.[J]. International journal of cardiology. 2026.
@article{corinna2026,
author = {Kroll Corinna and Hubert Astrid and Saccardi Leonie and Martínez Pereyra Valeria and Seitz Andreas and Sechtem Udo and Bekeredjian Raffi and Ong Peter},
title = {(Long-term) efficacy of endotype-based drug therapy on quality of life and symptom management in coronary vasomotion disorders.},
journal = {International journal of cardiology},
year = {2026},
note = {PMID: 42049126},
}
TY - JOUR AU - Kroll Corinna AU - Hubert Astrid AU - Saccardi Leonie AU - Martínez Pereyra Valeria AU - Seitz Andreas AU - Sechtem Udo AU - Bekeredjian Raffi AU - Ong Peter TI - (Long-term) efficacy of endotype-based drug therapy on quality of life and symptom management in coronary vasomotion disorders. T2 - International journal of cardiology PY - 2026 AN - PMID:42049126 ER -
In patients with angina despite non-obstructive coronary arteries (ANOCA), coronary vasomotion disorders (CVD) are a common cause for their symptoms. Due to the heterogeneous clinical presentation resulting from a broad spectrum of endotypes, symptom management still remains a major challenge. We aimed to demonstrate that endotype-based pharmacotherapy can improve angina severity and quality of life (QoL) outcomes in these patients.